Balaji Amines Q1 FY27 Results (NSE: BALAMINES)
Signal: Margin expansion
The read
Revenue inflected strongly (+25.6% YoY) after several quarters of decline, driven by improved realisations and product mix despite lower volumes. EBITDA margin expanded 900bps YoY to 26%, the second consecutive quarter of margin expansion, supported by both input cost tailwinds and operating leverage. The commissioning of India's first commercial DME plant opens a new growth vector in alternate fuels. PAT of ₹78 Cr represents the highest quarterly profit in at least the last 12 quarters, reversing a prolonged earnings downturn.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹461 Cr | 25.6% | 14.4% |
| EBIT | ₹121 Cr | 89.1% | |
| Net profit | ₹78 Cr | 110.8% | |
| EPS | ₹23.13 | 109.6% | |
| EBIT margin | 26% |
P&L walk
Revenue up 25.6% YoY to ₹461 Cr despite a 21.7% volume decline – steep price/mix improvement; EBITDA surged 89.1% YoY to ₹121 Cr and margin expanded 900bps YoY to 26%, driven by operating leverage and input tailwind; PAT more than doubled to ₹78 Cr.
Key positives
- EBITDA margin expanded 900bps YoY to 26%, the highest in at least 12 quarters – driven by input cost tailwinds and operating leverage.
- Pat more than doubled YoY to ₹78 Cr, the best quarterly profit in the prior 12-quarter series.
- Revenue grew 25.6% YoY despite a 21.7% volume decline, indicating strong pricing power and favourable mix shift to higher-value products.
- DME plant commissioning – India's first commercial-scale unit – diversifies into alternate fuels and import substitution, with significant growth optionality.
- Zero net debt on standalone balance sheet provides financial flexibility for ongoing capex.
Key concerns
- Volumes declined 21.7% YoY to 21,587 MT – revenue growth was entirely price/mix driven, not volume-based.
- Revenue still 20% below Q1FY24's ₹464 Cr level, indicating the recovery is partial despite the sharp YoY jump.
- Guidance remains qualitative; no quantified revenue or margin targets provided for FY27.
Research and educational content only. Not investment advice.